Clinical Trials
-
Principal Investigator:
James M. Noble, MD, MSFunded by a multi-year research grant from the National Institute on Aging, the DIAN ObservationalStudy enrolls family members who have parents with a mutated gene known to cause dominantlyinherited Alzheimers (DIAD). Through the study, researchers follow individuals and family members tosee if insights gained could lead to better understanding of how the disease progresses in order toidentify solutions to prevent DIAD or minimize its impact. -
Principal Investigator:
Philip L. De Jager, MD, PHDWe aim to identify new tools that will help us to achieve successful brain aging in the general population and in people with an underlying autoimmune disease. A critical aspect of this study is that we are looking for individuals who are willing to donate their brain and spinal cord when they pass away; this will enable the investigators to understand which molecules in the brain made someone more or less likely to age successfully. The brains will be housed at the New York Brain Bank. The study is primarily online, with online cognitive evaluations every three years. A subset of... -
Principal Investigator:
Chih-Chun Lin, MD, PhDWe are looking for participants for a study on the role of immune response in Parkinson's disease (PD) and Alzheimer's disease (AD). We are inviting people WITH PD, WITH AD, WITH MildCognitive Impairment or WITHOUT PD or AD to come and participate. We will be doing several questionnaires, a motor exam, and a short cognitive assessment, in addition to a blood draw of up to 250cc (17 tablespoons). This study will involve one to two visits for a total of up to 3 hours, and you will be compensated with $30.00 and a parking voucher. -
Principal Investigator:
Chih-Chun Lin, MD, PhDWe are looking for participants for a study on the role of immune response in Parkinson's disease (PD) and Alzheimer's disease (AD). We are inviting people WITH PD, WITH AD, or WITHOUT PD or AD to come and participate. We will be doing several questionnaires, a motor exam, and a short cognitive assessment, in addition to a blood draw of up to 250cc (17 tablespoons). This study will involve one to two visits for a total of up to 3 hours, and you will be compensated with $30.00 and a parking voucher. -
Principal Investigator:
Chih-Chun Lin, MD, PhDWe are looking for participants for a study on the role of immune response in Parkinson's disease (PD) and Alzheimer's disease (AD). We are inviting people WITH PD, WITH AD, or WITHOUT PD or AD to come and participate. We will be doing several questionnaires, a motor exam, and a short cognitive assessment, in addition to a blood draw of up to 250cc (17 tablespoons). This study will involve one to two visits for a total of up to 3 hours, and you will be compensated with $30.00 and a parking voucher. -
Principal Investigator:
Fabio M. Iwamoto, MDThe purpose of this study is to see how safe the study medicine, IGV-001 plus standard of care (SOC), is and to compare IGV-001 with placebo to see if it works in slowing glioblastoma multiforme (GBM) tumor regrowth. SOC refers to the usual medicine(s) or procedures used to treat your cancer. A placebo looks like the study medicine but does not contain any medication (active ingredient). Researchers use a placebo to see if a study medicine works better or is safer than not taking anything at all. -
Principal Investigator:
Fabio M. Iwamoto, MDThe purpose of this study is to see how safe the study medicine, IGV-001 plus standard of care (SOC), is and to compare IGV-001 with placebo to see if it works in slowing glioblastoma multiforme (GBM) tumor regrowth. SOC refers to the usual medicine(s) or procedures used to treat your cancer. A placebo looks like the study medicine but does not contain any medication (active ingredient). Researchers use a placebo to see if a study medicine works better or is safer than not taking anything at all. -
Principal Investigator:
Philip L. De Jager, MD, PHDThe Snapshot study aims to understand brain and spinal cord aging in healthy individuals and individuals with multiple sclerosis (MS). We aim to identify new tools that will help us to achieve successful brain aging in the general population and in people with an underlying autoimmune disease. A critical aspect of this study is that we are looking for individuals who are willing to donate their brain and spinal cord when they pass away; this will enable the investigators to understand which molecules in the brain made someone more or less likely to age successfully. The brains will be housed... -
Principal Investigator:
Philip L. De Jager, MD, PHDMS Genetics aims to better understand the genetic component of demyelinating diseases by doing genetic testing on blood samples of participants. This study involves a once time blood draw and completion of questionnaires spread out over a couple of years in hopes to better understand the genes that makes one predisposed to Multiple Sclerosis and various other demyelinating diseases. -
Principal Investigator:
Philip L. De Jager, MD, PHDWe need your help today to gather information about the experience of multiple sclerosis (MS) patients and the general population during the COVID-19 pandemic. Most MS patients take one of over a dozen of medications to control their disease, and these medications alter the immune system. These effects are not as strong as those experienced by patients with organ transplants or cancer patients on chemotherapy; however, we do not know today whether MS patients on medication are more susceptible to the virus. This study by the Columbia University MS Center in New York City aims to answer that...